Abstract:Introduction: Immune checkpoint inhibitors (ICIs) are important systemic therapeutic agents for hepatocellular carcinoma (HCC), among which T-cell immunoglobulin and mucin-domain containing protein 3 (Tim-3) is considered an emerging target for ICI therapy. This study aims to evaluate the prognostic value of Tim-3 expression and develop a predictive model for Tim-3 infiltration in HCC. Methods: We collected data from 424 HCC patients in The Cancer Genome Atlas (TCGA) and data from 102 pathologically confirmed HCC patients from our center for prognostic analysis. Multivariate Cox regression analyses were performed on both datasets to determine the prognostic significance of Tim-3 expression. In radiomics analysis, we used the K-means algorithm to cluster regions of interest in arterial phase enhancement and venous phase enhancement images from patients at our center. Radiomic features were extracted from three subregions as well as the entire tumor using pyradiomics. Five machine learning methods were employed to construct Habitat models based on habitat features and Rad models based on traditional radiomic features. The predictive performance of the models was compared using ROC curves, DCA curves, and calibration curves. Results: Multivariate Cox analyses from both our center and the TCGA database indicated that high Tim-3 expression is an independent risk factor for poor prognosis in HCC patients. Higher levels of Tim-3 expression were significantly associated with worse prognosis. Among the ten models evaluated, the Habitat model constructed using the LightGBM algorithm showed the best performance in predicting Tim-3 expression status (training set vs. test set AUC 0.866 vs. 0.824). Discussion: This study confirmed the importance of Tim-3 as a prognostic marker in HCC. The habitat radiomics model we developed effectively predicted intratumoral Tim-3 infiltration, providing valuable insights for the evaluation of ICI therapy in HCC patients.

Tim-3 Fosters HCC Development by Enhancing TGF-β-mediated Alternative Activation of Macrophages

Tim-3 expression and its role in hepatocellular carcinoma

Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling

Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma

Expression and Inhibitory Role of TIMP-3 in Hepatocellular Carcinoma.

Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis

Tim-3/galectin-9 Signaling Pathway Mediates T-cell Dysfunction and Predicts Poor Prognosis in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Timp-1 Activated Carcinoma-Associated Fibroblasts Inhibit Tumor Apoptosis by Activating Sdf1/Cxcr4 Signaling in Hepatocellular Carcinoma

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Tumor-Linked Macrophages Promote HCC Development by Mediating the CCAT1/Let-7b/HMGA2 Signaling Pathway

TIMP-3 Expression Associates with Malignant Behaviors and Predicts Favorable Survival in HCC.

Blocking Tim-3 Or/and PD-1 Reverses Dysfunction of Tumor-Infiltrating Lymphocytes in HBV-related Hepatocellular Carcinoma

TIMP-3 acts as suppressor gene in hepatocarcinoma

Blockade of TIM3 Relieves Immunosuppression Through Reducing Regulatory T Cells in Head and Neck Cancer.

Tim-3 in Regulating the Activity and Phenotype of Macrophage

The Role of Tumor-Associated Macrophages in Primary Hepatocellular Carcinoma and Its Related Targeting Therapy

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice

TIM3 Gene Polymorphisms in Patients with Chronic Hepatitis B Virus Infection: Impact on Disease Susceptibility and Hepatocellular Carcinoma Traits.

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

Unveiling Tim-3 immune checkpoint expression in hepatocellular carcinoma through abdominal contrast-enhanced CT habitat radiomics